End-of-day quote
Taipei Exchange
18:00:00 2024-06-06 EDT
|
5-day change
|
1st Jan Change
|
36.8
TWD
|
-2.65%
|
|
+0.27%
|
-3.79%
|
Fiscal Period: December |
2020
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
3,574
|
2,247
|
4,708
|
4,529
|
Enterprise Value (EV)
1 |
3,574
|
2,247
|
4,708
|
4,529
|
P/E ratio
|
-23.3
x
|
-12.2
x
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
55.3
x
|
30.2
x
|
EV / Revenue
|
-
|
-
|
55.3
x
|
30.2
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-64.7
x
|
FCF Yield
|
-
|
-
|
-
|
-1.55%
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
92,000
|
103,076
|
123,076
|
123,076
|
Reference price
2 |
38.85
|
21.80
|
38.25
|
36.80
|
Announcement Date
|
21-03-15
|
23-03-29
|
24-03-02
|
-
|
Fiscal Period: December |
2020
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
-
|
85.06
|
150
|
EBITDA
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-159.9
|
-143
|
Operating Margin
|
-
|
-
|
-188.02%
|
-95.33%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
Net income
|
-145.6
|
-184.5
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
EPS
|
-1.670
|
-1.790
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-70
|
FCF margin
|
-
|
-
|
-
|
-46.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-15
|
23-03-29
|
24-03-02
|
-
|
Fiscal Period: December |
2022 Q4
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
-
|
-
|
14.73
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-23.7
|
Operating Margin
|
-
|
-
|
-160.92%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
Net income
|
-53.32
|
-42.37
|
-
|
Net margin
|
-
|
-
|
-
|
EPS
|
-0.5200
|
-0.3600
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
23-03-29
|
23-11-06
|
24-03-02
|
Fiscal Period: December |
2020
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-70
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-23.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-23%
|
Assets
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
5
|
Capex / Sales
|
-
|
-
|
-
|
3.33%
|
Announcement Date
|
21-03-15
|
23-03-29
|
24-03-02
|
-
|
Last Close Price
36.8
TWD Average target price
48
TWD Spread / Average Target +30.43% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.79% | 140M | | +49.41% | 56.95B | | +41.65% | 40.26B | | -6.72% | 39.32B | | -5.96% | 28.37B | | +12.99% | 26.45B | | -19.82% | 19.41B | | +32.35% | 12.54B | | -0.08% | 12.15B | | +25.18% | 12.21B |
Other Biotechnology & Medical Research
|